Literature DB >> 11772697

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

Christian R Dolder1, Jonathan P Lacro, Laura B Dunn, Dilip V Jeste.   

Abstract

OBJECTIVE: Pharmacy refill records were used to compare medication adherence in outpatient veterans receiving typical versus atypical antipsychotic medications.
METHOD: Consecutive patients meeting selection criteria and receiving prescriptions for haloperidol (N=57), perphenazine (N=60), risperidone (N=80), olanzapine (N=63), and quetiapine (N=28) over a 3-month period were identified from a computerized database. The hospital policy at the time of this study required failure in trials of at least two typical antipsychotics before initiation of an atypical agent. Patients' adherence with the antipsychotic regimen was calculated by analyzing refill records for up to 12 months. The cumulative mean gap ratio (the number of days when medication was unavailable in relation to the total number of days) and the compliant fill rate (the number of prescription fills indicating adherence in relation to the total number of prescription fills) at 6 and 12 months were calculated.
RESULTS: Adherence rates at 6 and 12 months were moderately higher in patients who received atypical antipsychotics than in those who received typical agents. Cumulative mean gap ratios were 23.2% for typical and 14.1% for atypical antipsychotics at 12 months; thus, patients who received typical agents were without medication for an average of 7 days per month, compared with 4 days per month for those who received atypical agents. At 12 months, compliant fill rates were 50.1% for typical and 54.9% for atypical antipsychotics.
CONCLUSIONS: Interventions to improve adherence are warranted even for patients who receive atypical antipsychotic medications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772697     DOI: 10.1176/appi.ajp.159.1.103

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  75 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 2.  Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review.

Authors:  Jennifer B Levin; Anna Krivenko; Molly Howland; Rebecca Schlachet; Martha Sajatovic
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

3.  The future of pharmacotherapy for schizophrenia.

Authors:  John M Kane; Anil Malhotra
Journal:  World Psychiatry       Date:  2003-06       Impact factor: 49.548

4.  Changes in antipsychotic medication use after implementation of a Medicaid mental health carve-out in the US.

Authors:  John Robst
Journal:  Pharmacoeconomics       Date:  2012-05       Impact factor: 4.981

5.  'Real world' comparison of first- and second-generation antipsychotics in regard to length of inpatient hospitalization and number of re-hospitalizations.

Authors:  Claire Advokat; Benjamin D Hill; Joseph E Comaty
Journal:  Psychiatr Q       Date:  2007-12-01

6.  The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.

Authors:  Dawn I Velligan; Pamela M Diamond; Jim Mintz; Natalie Maples; Xueying Li; John Zeber; Larry Ereshefsky; Yui-Wing F Lam; Desiree Castillo; Alexander L Miller
Journal:  Schizophr Bull       Date:  2007-10-10       Impact factor: 9.306

Review 7.  Lack of insight in schizophrenia: impact on treatment adherence.

Authors:  Peter F Buckley; Donna A Wirshing; Prameet Bhushan; Joseph M Pierre; Seth A Resnick; William C Wirshing
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 8.  [Therapeutic drug monitoring in epileptology and psychiatry].

Authors:  C Brandt; P Baumann; G Eckermann; C Hiemke; T W May; B Rambeck; B Pohlmann-Eden
Journal:  Nervenarzt       Date:  2008-02       Impact factor: 1.214

9.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Authors:  Taishiro Kishimoto; Alfred Robenzadeh; Claudia Leucht; Stefan Leucht; Koichiro Watanabe; Masaru Mimura; Michael Borenstein; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2012-12-17       Impact factor: 9.306

Review 10.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.